Basal Insulin

Lilly’s Once-Weekly Insulin Delivers Similar A1C Reduction to Daily Basal Insulin

Sanofi to Build New State-of-the-Art Insulin Plant

6 Benefits of Combining Insulin and GLP-1 Drugs

Long-Acting Basaglar and the New Era of “Biosimilar” Insulin
What you need to know about the new insulin, its cost, dosing, and beyond!

Xultophy Beats Out Lantus in Major Clinical Trial
One of the biggest drug highlights at the 2015 ADA Scientific Sessions was a compelling presentation by diaTribe scientific Advisory Board member Dr. John Buse on brand new phase 3 clinical trial data comparing Xultophy (a GLP-1 agonist/long acting insulin combination taken as a single injection) to Lantus (a long acting insulin) for the treatment of type 2 diabetes. The results of the 26-week study were very impressive...

FDA Approves New Insulin Glargine Basaglar – The First “Biosimilar” Insulin in the US
Will this drug be cheaper than Lantus and other insulins?